docetaxel anhydrous has been researched along with lonafarnib in 3 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 224 | 34 | 90 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | lonafarnib (IC50) |
|---|---|---|---|
| Chain A, Protein farnesyltransferase alpha subunit | Rattus norvegicus (Norway rat) | 0.0019 | |
| Chain B, Protein farnesyltransferase beta subunit | Rattus norvegicus (Norway rat) | 0.0019 | |
| GTPase HRas | Homo sapiens (human) | 0.07 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 2.7 | |
| Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Bos taurus (cattle) | 0.0081 | |
| Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Homo sapiens (human) | 0.1498 | |
| Protein farnesyltransferase subunit beta | Bos taurus (cattle) | 0.0081 | |
| Protein farnesyltransferase subunit beta | Homo sapiens (human) | 0.1498 | |
| Protein farnesyltransferase subunit beta | Rattus norvegicus (Norway rat) | 0.0019 | |
| Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Rattus norvegicus (Norway rat) | 0.0019 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bishop, WR; Hajian, G; Liu, M; Nielsen, LL; Shi, B; Terracina, G; Yaremko, B | 1 |
| Bishop, WR; Hsieh, Y; Kirschmeier, P; Liu, G; Long, BJ; Marrinan, CH; Taylor, SA | 1 |
| Bender, L; Chanel-Vos, C; Escuin, D; Fanucchi, MP; Gal, A; Giannakakou, P; Harvey, RD; Kauh, J; Khuri, FR; Kutner, M; Marcus, A; Pan, L; Ramalingam, SS; Saba, N; Shin, DM | 1 |
1 trial(s) available for docetaxel anhydrous and lonafarnib
| Article | Year |
|---|---|
Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Male; Middle Aged; Neoplasms; Pilot Projects; Piperidines; Pyridines; Taxoids | 2011 |
2 other study(ies) available for docetaxel anhydrous and lonafarnib
| Article | Year |
|---|---|
The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents, Phytogenic; Cell Division; Docetaxel; Drug Synergism; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Male; Mice; Mice, Nude; Mice, Transgenic; Paclitaxel; Piperidines; Pyridines; Taxoids; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |
Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Drug Therapy, Combination; Humans; Male; Mice; Mice, Nude; Mice, SCID; Neoplasms, Hormone-Dependent; Piperidines; Prostatic Neoplasms; Pyridines; Taxoids; Xenograft Model Antitumor Assays | 2009 |